HighTower Advisors’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
Other funds holding CAPR
SCM
TCM
RCM
HighTower Advisors's CAPR Position: Q4 2025 in Review
HighTower Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 1,200 shares — an estimated $8.65K sold.
HighTower Advisors first reported a position in CAPR in Q2 2020 and held it in 17 quarters. The position peaked at $215K in Q3 2021. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.
- HighTower Advisors reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
- HighTower Advisors sold 1,200 Capricor Therapeutics shares in Q4 2025, an estimated $8.65K.
- HighTower Advisors first reported a position in Capricor Therapeutics in Q2 2020 and held it in 17 quarters.
- HighTower Advisors's Capricor Therapeutics position peaked at $215K in Q3 2021.
- 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.
Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.